Novartis Ag (NVSEF) SEC Filings — 2024
19 SEC filings for Novartis Ag (NVSEF) in 2024.
Filings
- Novartis SMA Drug Hits Phase III Endpoint — 6-K · Dec 30, 2024
- Novartis Upgrades Guidance, Highlights Pipeline — 6-K · Nov 25, 2024
- Novartis AG Files Q3 2024 Financial Report — 6-K · Oct 29, 2024
- Novartis Scemblix FDA Approved for Newly Diagnosed CML — 6-K · Oct 29, 2024
- Novartis AG Files SC 13D/A Amendment for MorphoSys AG — SC 13D/A · Oct 17, 2024
- Novartis Issues Over $3.7 Billion in New Notes — 6-K · Sep 18, 2024
- FDA Approves Novartis Kisqali for Early Breast Cancer — 6-K · Sep 17, 2024
- Novartis AG Files SC 13D/A Amendment for MorphoSys AG — SC 13D/A · Aug 15, 2024
- Novartis Fabhalta FDA Accelerated Approval for IgAN — 6-K · Aug 8, 2024
- Novartis AG Files Q2 2024 Financial Report — 6-K · Jul 18, 2024
- Novartis AG Amends MorphoSys AG Filing — SC 13D/A · Jun 21, 2024
- Novartis AG Amends Schedule 13D for MorphoSys AG — SC 13D/A · Jun 17, 2024
- Novartis Amends MorphoSys Acquisition Filing — SC 13D/A · Jun 10, 2024
- Novartis AG Amends MorphoSys AG Filing — SC 13D/A · May 28, 2024
- Novartis AG Files Q1 2024 Financial Reports — 6-K · Apr 23, 2024
- Novartis Launches Tender Offer for MorphoSys AG — SC 13D · Apr 18, 2024
- BlackRock Amends Novartis Stake, Maintains Passive Position — SC 13G/A · Feb 2, 2024
- Novartis AG Files 20-F Report for Fiscal Year Ended December 31, 2023 — 20-F · Jan 31, 2024
- Novartis Scemblix® Beats Standard TKIs in CML Phase III Trial — 6-K · Jan 8, 2024